Introduction
============

Phthalates are common industrial chemicals used in cosmetics, personal care products, plastics, and building materials. Exposures are frequent, but the contributions of specific sources are poorly characterized. Phthalates represent a broad chemical class that includes both low-molecular-weight (LMW) compounds such as diethyl phthalate (DEP) and relatively high-molecular-weight (HMW) compounds such as diethylhexyl phthalate (DEHP) and butylbenzyl phthalate (BBzP). LMW phthalates are most commonly found in cosmetics and personal care products, whereas HMW phthalates are most associated with plastics, particularly polyvinyl chloride (PVC) building materials ([@r7]; [@r9]; [@r17]). Results from dietary intervention studies suggest that food packaging is the primary source of human exposure to DEHP, but not BBzP ([@r32]; [@r42]). BBzP exposure is associated with PVC flooring and other building materials in the home ([@r9]).

Phthalates and other plasticizing chemicals have been associated with wheeze, allergies, and asthma among children ([@r5]; [@r6]; [@r12]; [@r23]; [@r27], [@r28]; [@r34]; [@r38]) and adults ([@r26]; [@r25]). Recent studies have measured phthalate levels in urine or dust, although earlier studies suggested a role for phthalates due to the presence of plastic materials in the home ([@r26]; [@r38]), exposure to PVC plastics in an occupational setting ([@r26]) or use of synthetic bedding ([@r40]). As the evidence for a potential role for phthalates in respiratory and allergic outcomes has increased, there is greater interest in HMW phthalates such as DEHP and BBzP, with evidence both from human and animal studies ([@r13]; [@r14]; [@r26]; [@r33]; [@r37]; [@r39]). These HMW phthalates alter immune responses in animal and *in vitro* models ([@r33]; [@r37]). In addition, other studies suggest that DEHP and other plasticizers may act as adjuvants to enhance the allergic response ([@r30]).

Recent reports have stressed the need to understand the potential allergic health effects of phthalates ([@r15]; [@r24]; [@r36]). Although some evidence suggests a role of phthalates in the etiology of allergic sensitization and allergic symptoms, there is a paucity of population-based data, particularly among adults. To address this, we evaluated the association of specific phthalate metabolites with measures of allergic symptoms and sensitization in a representative sample of the U.S. population, the National Health and Nutrition Examination Survey (NHANES) 2005--2006.

Methods
=======

We used publicly available data from NHANES 2005--2006 \[Centers for Disease Control and Prevention ([@r11])\] to evaluate the association of phthalates and allergy. NHANES 2005--2006 collected detailed data on allergic symptoms and sensitization, so both questionnaire and biochemical measures of allergy are available for all NHANES participants \> 1 year of age (*n* = 8,338). At the time of recruitment, all study participants provided informed consent. All data were anonymized prior to becoming publicly available. Urinary phthalate concentrations were measured in a random sample of participants ≥ 6 years of age (*n* = 2,548). Our analysis is limited to the 2,325 individuals who had complete information on allergy, urinary phthalate concentrations, and model covariates.

We assessed both self-reported current allergic symptoms and allergic sensitization as measured by specific IgE (sIgE). Information on current allergic symptoms was obtained from self-administered questionnaires completed at the NHANES clinic visit. Subjects \< 16 years of age were interviewed with a proxy respondent, usually a parent, responsible for completing the interview. The questionnaire asked about six allergic conditions (asthma, wheeze, hay fever, allergy, itchy rash, and rhinitis) in the past year.

Serum samples were analyzed for allergen-specific IgEs using the Pharmacia Diagnostics ImmunoCAP 1000 System (Kalamazoo, MI, USA). A total of 19 allergen-specific IgEs *(Dermatophagoides farinae, Dermatophagoides pteronyssinus*, cat, dog, cockroach, *Alternaria alternata,* peanut, egg white, cow's milk, ragweed, rye grass, bermuda grass, oak, birch, shrimp, *Aspergillus fumigatus*, Russian thistle, mouse, and rat) were assessed. Individuals who tested positive (≥ 0.35 kU/L) to at least one allergen were considered allergen sensitized (sIgE positive). Information on sensitization to specific allergens from NHANES 2005--2006 has been published elsewhere ([@r43]).

Fifteen phthalate metabolites were measured in spot urine samples using high performance liquid chromatography--electrospray ionization--tandem mass spectrometry (HPLC-ESI-MS/MS) at the National Center for Environmental Health laboratory (CDC, Atlanta, GA, USA) ([@r10]). Four of these analytes were primary \[mono-(2-ethyl)-hexyl phthalate (MEHP)\] or secondary metabolites \[mono-2-ethyl-5-carboxypentyl phthalate (MECPP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP)\] of DEHP. We summed the concentrations of all four metabolites to create a summary DEHP variable (ΣDEHP) for analysis; individual DEHP metabolites were not analyzed because of their common sources and the resulting high correlation among these metabolites (77--98%). We analyzed all chemicals that were detected in ≥ 25% of the population; for values below the detection limit, we assigned a value of the limit of detection (LOD) divided by the square root of 2 ([@r22]).

Information on covariates was obtained either via questionnaire (e.g., demographic characteristics, smoking status) or via measurement \[e.g., body mass index (BMI)\]. Urinary creatinine levels were measured using the Jaffe rate reaction with a CX3 analyzer (Beckman Instruments, Brea, CA, USA).

We used logistic regression models adjusted for study design using sampling weights to estimate associations of urinary phthalates with measures of allergic sensitization and allergic symptoms. Urinary phthalate concentrations were log~10~-transformed because of nonnormality of the distribution. Models were adjusted for age (continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other), gender, creatinine (log~10~ transformed, continuous), BMI (categories), and cotinine (categories). Cotinine was classified as \< LOD (0.015 ng/mL), low exposure (\< 10 ng/mL) and high exposure (≥ 10 ng/mL). For adults, BMI was calculated as body weight in kilograms divided by height in meters squared and categorized as underweight or normal (\< 25), overweight (25 to 30), or obese (≥ 30). For children, BMI was classified as the age percentile underweight or normal (\< 85th percentile), overweight (85--95th percentile), obese (≥ 95th percentile) ([@r35]). Similar modeling strategies have been employed for previous analyses of these outcomes in the NHANES 2005--2006 data ([@r43]). We also evaluated poverty income ratio \[PIR, three categories: low (≤ 1.3), middle (1.3--3.5), and high (\> 3.5) income\] as a potential confounder because previous analyses have shown an association between socioeconomic status and phthalate concentrations in women ([@r31]) and allergic sensitization in children in NHANES 2005--2006 ([@r45]). Adjustment for PIR did not substantially alter our odds ratio (OR) estimates. Therefore, to maximize the observations included in our models, we did not include PIR as a covariate (100 missing observations). Data for children (6--17 years of age) and adults were analyzed separately because both the covariate structure and the outcome prevalence differed between adults and children. Because phthalate concentrations and allergic sensitization rates differ by race/ethnicity, we assessed potential interaction by race/ethnicity in four categories by including three two-way interaction terms in our models and performed a likelihood ratio test (3 degrees of freedom) comparing the fit of models with and without the interaction terms to assess whether statistical interaction was present. In addition, we explored whether findings for monobenzyl phthalate (MBzP) and allergic symptoms were related to allergic sensitization by expanding our logistic regression models to four-level polytomous models (allergic sensitization + symptom, symptom without sensitization, sensitization without symptom, and no symptom + no sensitization) for each of the four symptoms (asthma, wheeze, rhinitis, hay fever). To test whether the ORs differed across the four strata, we used a contrast statement; a *p*-value for difference was the result of this contrast test. All statistical modeling was done using survey procedures in SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA). A *p*-value ≤ 0.05 was considered statistically significant.

Results
=======

Rhinitis was the most common symptom among both children and adults ([Table 1](#t1){ref-type="table"}). Current hay fever was reported half as often in children (3.6%) as in adults (7.4%). Allergen sensitization was common, with 46% of children and 44% of adults being sensitized to at least one sIgE.

###### 

Demographic, medical, and allergic characteristics for the adults (*n* = 1,546) and children 6--17 years of age (*n* = 779) with urinary phthalate metabolite data, NHANES 2005--2006.

  Characteristic                                                                                                                                                                                                                                                                                                            Children   Adults                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ------------ ------------ ------------ ------------
  Age (years)^*a*^                                                                                                                                                                                                                                                                                                          779        11.9 (0.1)   1,546        45.6 (0.9)   
  Race/ethnicity                                                                                                                                                                                                                                                                                                            EGPhE      216          63.5 (3.8)   752          72.2 (3.1)
  Non-Hispanic black                                                                                                                                                                                                                                                                                                        223        12.3 (2.0)   372          11.6 (2.2)   
  Mexican American                                                                                                                                                                                                                                                                                                          274        13.2 (1.7)   311          7.7 (1.0)    
  Other                                                                                                                                                                                                                                                                                                                     66         10.9 (1.9)   111          8.4 (1.3)    
  Gender                                                                                                                                                                                                                                                                                                                    EGPhE      372          47.1 (2.3)   792          51.1 (1.7)
  Male                                                                                                                                                                                                                                                                                                                      407        52.9 (2.3)   754          48.9 (1.7)   
  Cotinine (ng/mL)                                                                                                                                                                                                                                                                                                          EGPhE      169          22.0 (3.3)   286          17.9 (2.0)
  Low (≥ 0.015--10)                                                                                                                                                                                                                                                                                                         564        71.3 (3.4)   849          52.7 (2.0)   
  High (≥ 10)                                                                                                                                                                                                                                                                                                               46         6.7 (0.9)    411          29.5 (1.1)   
  BMI^*b*^                                                                                                                                                                                                                                                                                                                  EGPhE      505          70.7 (2.4)   494          33.2 (1.4)
  Overweight                                                                                                                                                                                                                                                                                                                123        16.4 (1.9)   515          32.1 (1.4)   
  Obese                                                                                                                                                                                                                                                                                                                     151        12.9 (2.1)   537          34.8 (1.7)   
  Current allergic conditions^*c*^                                                                                                                                                                                                                                                                                          EGPhE      125          18.1 (2.6)   290          22.9 (1.0)
  Asthma                                                                                                                                                                                                                                                                                                                    65         8.4 (1.2)    116          7.4 (0.8)    
  Hay fever                                                                                                                                                                                                                                                                                                                 23         3.6 (0.9)    88           7.4 (0.9)    
  Itchy rash                                                                                                                                                                                                                                                                                                                43         5.2 (1.0)    118          7.8 (0.7)    
  Rhinitis                                                                                                                                                                                                                                                                                                                  188        27.6 (2.7)   498          35.4 (1.2)   
  Wheeze                                                                                                                                                                                                                                                                                                                    80         10.7 (1.6)   219          16.6 (1.3)   
  Allergic sensitization---any sIgE                                                                                                                                                                                                                                                                                         406        46.1 (2.8)   717          44.0 (1.0)   
  ^***a***^Weighted mean is reported for age. ^***b***^Child BMI covariate is age percentile; adult BMI covariate is actual BMI (kg/m^2^). ^***c***^Self-reported current symptoms in past 12 months; current symptoms of asthma, hay fever, or allergy were assessed only among those who reported a doctor's diagnosis.                                                     

Both LMW and HMW phthalates were detected in the urine of all participants ([Table 2](#t2){ref-type="table"}). Monoethyl phthalate (MEP) was the most commonly detected LMW phthalate metabolite. All the HMW phthalate metabolites, except mono-isononyl phthalate (MiNP), mono-cyclohexyl phthalate (MCHP), and mono-*n*-octyl phthalate (MOP) were detectable in the majority of samples. The distributions of all LMW and HMW phthalates spanned three orders of magnitude. Concentrations and distributions of phthalates were similar for children and adults (see Supplemental Material, Tables S1 and S2, respectively).

###### 

Urinary phthalate metabolite concentrations (μg/L) for NHANES 2005--2006 participants.

  Metabolite                                                                                                                                                                                                                                                                                                                                                 LOD                                       \> LOD (%)   GM (GSE)   Percentile                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ------------ ---------- --------------- -------- -------- -------- -------- ---------
  LMW                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  MiBP                                                                                                                                                                                                                                                                                                                                                       Mono-isobutyl phthalate                   0.3          97.1       5.19 (0.30)     0.47     2.48     5.70     11.75    31.96
  MnBP                                                                                                                                                                                                                                                                                                                                                       Mono-*n*-butyl phthalate                  0.6          99.5       19.55 (0.81)    2.91     10.19    20.06    39.88    106.30
  MEP                                                                                                                                                                                                                                                                                                                                                        Monoethyl phthalate                       0.5          99.6       109.24 (6.33)   11.92    38.52    101.83   288.68   1457.35
  MMP                                                                                                                                                                                                                                                                                                                                                        Mono-*n*-methyl phthalate                 1.1          38.0       1.51 (0.07)     \< LOD   \< LOD   \< LOD   2.52     12.46
  HMW                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  MBzP                                                                                                                                                                                                                                                                                                                                                       Monobenzyl phthalate                      0.2          98.4       8.22 (0.52)     0.68     3.72     8.73     20.45    66.64
  MCOP                                                                                                                                                                                                                                                                                                                                                       Mono(carboxyoctyl) phthalate              0.7          95.1       5.35 (0.36)     0.55     2.35     4.98     10.86    52.74
  MCNP                                                                                                                                                                                                                                                                                                                                                       Mono(carboxynonyl) phthalate              0.6          89.9       2.71 (0.11)     \< LOD   1.32     2.61     5.21     17.42
  MCPP                                                                                                                                                                                                                                                                                                                                                       Mono-(3-carboxypropyl) phthalate          0.2          96.1       2.04 (0.10)     0.22     0.98     2.02     4.21     13.04
  MCHP                                                                                                                                                                                                                                                                                                                                                       Mono-cyclohexyl phthalate                 0.6          2.2        0.44 (0.00)     \< LOD   \< LOD   \< LOD   \< LOD   \< LOD
  MiNP                                                                                                                                                                                                                                                                                                                                                       Mono-isononyl phthalate                   1.2          13.0       1.05 (0.02)     \< LOD   \< LOD   \< LOD   \< LOD   3.52
  MOP                                                                                                                                                                                                                                                                                                                                                        Mono-*n*-octyl phthalate                  1.8          1.1        1.32 (0.00)     \< LOD   \< LOD   \< LOD   \< LOD   \< LOD
  ∑DEHP                                                                                                                                                                                                                                                                                                                                                      ∑Diethylhexyl phtalate                                            85.47 (4.10)    11.36    36.23    77.28    174.02   930.24
  MEHP                                                                                                                                                                                                                                                                                                                                                       Mono-(2-ethyl)-hexyl phthalate            1.2          66.6       3.01 (0.13)     \< LOD   \< LOD   2.40     6.26     41.37
  MECPP                                                                                                                                                                                                                                                                                                                                                      Mono-2-ethyl-5-carboxypentyl phthalate    0.6          100.0      38.28 (1.90)    5.10     16.44    34.40    78.83    384.99
  MEHHP                                                                                                                                                                                                                                                                                                                                                      Mono-(2-ethyl-5-hydroxyhexyl) phthalate   0.7          99.8       25.35 (1.23)    2.85     10.51    23.33    55.02    305.09
  MEOHP                                                                                                                                                                                                                                                                                                                                                      Mono-(2-ethyl-5-oxohexyl) phthalate       0.7          98.9       16.14 (0.81)    1.85     6.63     14.99    35.30    184.95
  Abbreviations: GM, geometric mean; GSE, geometric standard error of the mean. Below LOD fill values were determined as LOD divided by the square root of 2; imputed values were used in the calculation of GM (GSE). Restricted to participants with all covariates in logistic regression model age, race/ethnicity, gender, cotinine, BMI, creatinine.                                                                                                                         

MBzP was the metabolite most consistently associated with allergic symptoms in adults ([Table 3](#t3){ref-type="table"}). It was positively associated with current asthma \[OR = 1.46; 95% confidence interval (CI): 1.01, 2.11\], current wheeze (OR = 1.78; 95% CI: 1.22, 2.60), current hay fever (OR = 1.68; 95% CI: 1.09, 2.59), and current rhinitis (OR = 1.24; 95% CI: 1.01, 1.52). In models adjusted for PIR, the OR for MBzP and current asthma increased (1.54; 95% CI: 0.98, 2.42) but was no longer statistically significant; no other estimates changed their statistical significance after PIR adjustment. No other HMW phthalate metabolite was significantly associated with allergic symptoms in adults. Current asthma in children was inversely associated with ΣDEHP and mono(carboxyoctyl) phthalate (MCOP), but not with MBzP or other HMW metabolites ([Table 4](#t4){ref-type="table"}). Individual metabolites also were inversely associated with current hay fever in children, specifically, the butyl phthalate metabolites mono-isobutyl phthalate (MiBP) and mono-*n*-butyl phthalate (MnBP), as well as mono-(3-carboxylpropyl) phthalate (MCPP), and MBzP. MEP was inversely associated with current hay fever in adults, but not children. No phthalates were associated with current itchy rash or current allergy in either children or adults (data not shown).

###### 

Associations \[OR (95% CI)^*a*^\] between urinary phthalate metabolite concentration and current allergic symptoms in adults (*n* = 1,596), NHANES 2005--2006.

  Metabolite                                                                                                                                               Current asthma (*n* = 116)   Current wheeze (*n* = 219)   Current hay fever (*n* = 88)   Current rhinitis (*n* = 498)
  -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ---------------------------- ------------------------------ ------------------------------
  LMW                                                                                                                                                                                                                                               
  MiBP                                                                                                                                                     1.39 (0.77, 2.50)            0.92 (0.57, 1.48)            0.93 (0.46, 1.87)              0.99 (0.76, 1.29)
  MnBP                                                                                                                                                     1.75 (0.67, 4.56)            1.36 (0.74, 2.53)            1.23 (0.54, 2.79)              1.34 (0.83, 2.17)
  MEP                                                                                                                                                      1.12 (0.80, 1.57)            1.06 (0.81, 1.39)            0.68 (0.47, 1.00)              1.03 (0.85, 1.23)
  MMP                                                                                                                                                      1.29 (0.70, 2.37)            1.20 (0.80, 1.79)            0.59 (0.33, 1.05)              0.91 (0.66, 1.25)
  HMW                                                                                                                                                                                                                                               
  MBzP                                                                                                                                                     1.46 (1.01, 2.11)            1.78 (1.22, 2.60)            1.68 (1.09, 2.59)              1.24 (1.01, 1.52)
  MCOP                                                                                                                                                     0.96 (0.73, 1.25)            0.83 (0.58, 1.18)            0.64 (0.37, 1.11)              0.97 (0.76, 1.25)
  MCNP                                                                                                                                                     0.99 (0.65, 1.49)            1.09 (0.79, 1.52)            0.66 (0.41, 1.07)              0.93 (0.59, 1.44)
  MCPP                                                                                                                                                     1.40 (0.78, 2.54)            1.41 (0.85, 2.34)            0.83 (0.43, 1.60)              0.98 (0.74, 1.30)
  ∑DEHP                                                                                                                                                    1.16 (0.82, 1.64)            1.23 (0.86, 1.77)            1.09 (0.59, 2.01)              1.09 (0.86, 1.38)
  All models were adjusted for age, race, gender, BMI, creatinine, and cotinine. ^***a***^ORs for 1-log~10~ increase in urinary phthalate concentration.                                                                                            

###### 

Associations \[OR (95% CI)^*a*^\] between urinary phthalate metabolite concentrations and current allergic symptoms in children 6--17 years of age (*n* = 779), NHANES 2005--2006.

  Metabolite                                                                                                                                               Current asthma (*n* = 65)   Current wheeze (*n* = 80)   Current hay fever (*n* = 23)   Current rhinitis (*n* = 188)
  -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- --------------------------- ------------------------------ ------------------------------
  LMW                                                                                                                                                                                                                                             
  MiBP                                                                                                                                                     0.92 (0.26, 3.29)           1.08 (0.49, 2.35)           0.12 (0.04, 0.39)              0.84 (0.53, 1.33)
  MnBP                                                                                                                                                     0.63 (0.20, 2.02)           0.45 (0.20, 0.98)           0.07 (0.03, 0.17)              0.83 (0.46, 1.52)
  MEP                                                                                                                                                      0.90 (0.44, 1.85)           0.99 (0.46, 2.16)           0.58 (0.16, 2.13)              0.89 (0.65, 1.23)
  MMP                                                                                                                                                      1.15 (0.68, 1.95)           1.10 (0.67, 1.80)           1.01 (0.31, 3.25)              1.32 (0.80, 2.17)
  HMW                                                                                                                                                                                                                                             
  MBzP                                                                                                                                                     1.06 (0.33, 3.45)           0.92 (0.35, 2.37)           0.42 (0.22, 0.79)              1.02 (0.62, 1.67)
  MCOP                                                                                                                                                     0.74 (0.36, 1.52)           1.16 (0.65, 2.07)           0.54 (0.11, 2.56)              1.40 (0.83, 2.37)
  MCNP                                                                                                                                                     0.50 (0.25, 0.97)           0.81 (0.31, 2.12)           0.76 (0.13, 4.58)              1.23 (0.71, 2.13)
  MCPP                                                                                                                                                     0.69 (0.33, 1.43)           0.87 (0.48, 1.58)           0.12 (0.02, 0.63)              1.02 (0.65, 1.58)
  ∑DEHP                                                                                                                                                    0.26 (0.14, 0.49)           0.58 (0.24, 1.42)           0.78 (0.18, 3.48)              1.52 (0.86, 2.66)
  All models were adjusted for age, race, gender, BMI, creatinine, and cotinine. ^***a***^ORs for 1-log~10~ increase in urinary phthalate concentration.                                                                                          

Phthalate metabolites, particularly those from HMW chemicals, were positively associated with allergic sensitization in adults, but not in children ([Table 5](#t5){ref-type="table"}). Specifically, ΣDEHP and MCPP were significantly associated with being sIgE positive. Conversely, MEP was inversely associated with allergic sensitization in adults; other LMW phthalates were not. Similar findings were observed when we analyzed allergen subgroups (e.g., indoor allergens; data not shown).

###### 

ORs (95% CIs)^*a*^ for sIgE sensitization^*b*^ with urinary phthalate metabolite concentration in adults and children 6--17 years of age, NHANES 2005--2006.

  Metabolite                                                                                                                                                                                                                   Adults              Children
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- -------------------
  LMW                                                                                                                                                                                                                                              
  MiBP                                                                                                                                                                                                                         1.32 (0.99, 1.76)   0.93 (0.51, 1.70)
  MnBP                                                                                                                                                                                                                         1.14 (0.74, 1.74)   1.14 (0.68, 1.93)
  MEP                                                                                                                                                                                                                          0.79 (0.70, 0.90)   1.24 (0.80, 1.94)
  MMP                                                                                                                                                                                                                          0.88 (0.65, 1.20)   0.83 (0.56, 1.23)
  HMW                                                                                                                                                                                                                                              
  MBzP                                                                                                                                                                                                                         1.41 (0.96, 2.06)   1.18 (0.74, 1.86)
  MCOP                                                                                                                                                                                                                         1.21 (0.95, 1.54)   0.69 (0.40, 1.18)
  MCNP                                                                                                                                                                                                                         1.23 (0.86, 1.75)   0.73 (0.44, 1.23)
  MCPP                                                                                                                                                                                                                         1.53 (1.12, 2.10)   0.69 (0.46, 1.03)
  ∑DEHP                                                                                                                                                                                                                        1.41 (1.12, 1.79)   1.14 (0.79, 1.65)
  All models adjusted for age, race, gender, BMI, creatinine, and cotinine. ^***a***^OR for 1 log~10~ unit change in urinary phthalate level. ^***b***^Positive for at least one of 19 allergen-specific IgEs (≥ 0.35 kU/L).                       

When we evaluated potential interactions by race/ethnicity, only the interaction between MEP and sIgE sensitization in adults was statistically significant (interaction *p*-value \< 0.001). As shown in [Figure 1A](#f1){ref-type="fig"}, a log~10~ increase in MEP concentration was positively associated with sensitization in Mexican-American adults, but inversely associated with sensitization in all other adult race/ethnicity groups. Among children, the interaction by race/ethnicity was not significant and the pattern was less clear. The results suggested that in Mexican-American children, there was a positive association with MEP and sIgE (OR = 1.38; 95% CI: 0.92, 2.07; [Figure 1B](#f1){ref-type="fig"}) and potentially an association with children of other race/ethnicity (OR = 3.72; 95% CI: 0.87, 15.87); however, the sample size was small and the CI wide, and there was no association among non-Hispanic whites and blacks.

![MEP and allergic sensitization by race in adults (*A*) and children 6--17 years of age (*B*).](ehp.1206211.g001){#f1}

The results from polytomous regression models of associations between MBzP and each of the four symptoms (asthma, wheeze, rhinitis, hay fever) in the presence or absence of allergic sensitization (allergic sensitization + symptom, symptom without sensitization, sensitization without symptom, and no symptom + no sensitization) suggest that adults with allergen sensitization were more likely to have wheeze (*p*~difference~ \< 0.001) and asthma (*p*~difference~ = 0.011) associated with MBzP than those without sensitization or with allergic sensitization alone ([Table 6](#t6){ref-type="table"}). For hay fever and rhinitis there was no statistical difference in the ORs for those with and without sensitization. For children, although there was no association with MBzP with allergic sensitization or symptoms alone, when we assessed the symptoms based on allergic sensitization status, individuals with both allergic sensitization and symptoms had the highest odds of exposure. Although the individual ORs had 95% CIs that included the null value, the contrast tests for differences among the ORs indicated significant differences for wheeze based on 80 cases (*p*~difference~ = 0.047) and hay fever based on 23 cases (*p*~difference~ = 0.011).

###### 

ORs (95% CIs)^*a*^ for MBzP and allergic symptoms, stratified by allergic sensitization in adults and children 6--17 years of age, NHANES 2005--2006.

  Symptom/outcome                                                                                                                                                                                                               Adults   Children                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------- ------------------- ---------- ----- -------------------- -------
  Asthma                                                                                                                                                                                                                                                                                           
  No sensitization, no asthma                                                                                                                                                                                                   786      1.00                           353   1.00                 
  Current asthma only                                                                                                                                                                                                           40       0.71 (0.38, 1.31)              18    0.485 (0.16, 1.47)   
  Allergen sensitized only                                                                                                                                                                                                      635      1.27 (0.85, 1.90)              358   1.078 (0.68, 1.70)   
  Allergen sensitized and asthma                                                                                                                                                                                                76       2.53 (1.43, 4.46)   0.011      47    1.55 (0.36, 6.67)    0.210
  Hay fever                                                                                                                                                                                                                                                                                        
  No sensitization, no hay fever                                                                                                                                                                                                806      1.00                           365   1.00                 
  Hay fever only                                                                                                                                                                                                                19       2.28 (1.12, 4.64)              4     0.03 (0.004, 0.31)   
  Allergen sensitized only                                                                                                                                                                                                      647      1.37 (0.92, 2.06)              387   1.08 (0.70, 1.65)    
  Allergen sensitized and hay fever                                                                                                                                                                                             69       1.87 (1.02, 3.44)   0.310      19    1.57 (0.29, 8.41)    0.011
  Rhinitis                                                                                                                                                                                                                                                                                         
  No sensitization, no rhinitis                                                                                                                                                                                                 591      1.00                           310   1.00                 
  Rhinitis only                                                                                                                                                                                                                 235      1.21 (0.87, 1.69)              61    0.61 (0.31, 1.21)    
  Allergen sensitized only                                                                                                                                                                                                      455      1.40 (0.89, 2.21)              280   0.95 (0.59, 1.55)    
  Allergen sensitized and rhinitis                                                                                                                                                                                              260      1.70 (1.07, 2.71)   0.481      126   1.38 (0.63, 3.04)    0.144
  Wheeze                                                                                                                                                                                                                                                                                           
  No sensitization, no wheeze                                                                                                                                                                                                   730      1.00                           351   1.00                 
  Wheeze only                                                                                                                                                                                                                   96       1.34 (0.66, 2.73)              20    0.32 (0.10, 1.06)    
  Allergen sensitized only                                                                                                                                                                                                      594      1.25 (0.84, 1.85)              345   1.05 (0.65, 1.68)    
  Allergen sensitized and wheeze                                                                                                                                                                                                123      2.74 (1.55, 4.83)   \< 0.001   60    1.57 (0.50, 4.98)    0.047
  All models adjusted for age, race, gender, BMI, creatinine, and cotinine. ^***a***^ORs for 1 log~10~ increase in MBzP concentration. ^***b***^*p*-Value for difference of ORs using contrast statement in polytomous model.                                                                      

Discussion
==========

Our most consistent finding was for MBzP and allergic symptoms in adults. MBzP was positively associated with current asthma, current wheeze, current hay fever, and current rhinitis as well as, but nonsignificantly, with allergic sensitization. There was some suggestion that the association between MBzP and allergic symptoms was driven by allergic sensitization, but the evidence was not strong. MBzP is the primary metabolite of BBzP, an HMW phthalate used in plastics and other materials in the home. In a population-based case--control study conducted from 1997 to 2000, [@r25] reported that plastic wall materials in the home were associated with incident asthma among 1,453 Finnish adults. There is increasing evidence that MBzP may be associated with allergic outcomes. Prenatal urinary MBzP levels were associated with the development of eczema by 5 years of age in 407 children in a birth cohort study ([@r28]) and with increased airway inflammation as measured by exhaled nitric oxide ([@r27]). In a cross-sectional study of 101 Taiwanese children 3--9 years of age, BBzP concentration in house dust was associated with allergic symptoms and asthma ([@r23]). Although some phthalates, particularly di-*n*-butyl phthalate, are included in pharmaceuticals ([@r19]), BBzP is not approved for pharmaceutical use and, thus, MBzP in urine is unlikely to be a consequence of the use of allergy or asthma medications.

Much of the mechanistic work to date on phthalates and allergy has focused on DEHP and its ability to modulate responses to allergens ([@r26]; [@r30]). In murine models and in human lung epithelial cells, DEHP, but not BBzP, has been shown to have an adjuvant effect on immune response to allergens ([@r16]; [@r33]; [@r37]; [@r39]). In a small human study, 16 adults with sensitivity to house dust mites and 16 without sensitivity were exposed to airborne dust containing low or high levels of DEHP. Those exposed to high levels had an attenuated immune response, whereas those exposed at low levels had mucosal inflammation and nonsensitized individuals had no response ([@r14]). In murine models, BBzP enhanced anti-ovalbumin responses at high doses, but not at the lower doses potentially more consistent with human exposures ([@r13]). Few studies have evaluated whether BBzP, or its metabolite MBzP, have independent effects on immune responses at levels relevant to human exposure. One study reported that topical administration of BBzP did not stimulate an immune response in mice ([@r8]). Our results for DEHP and allergic sensitization in adults are consistent with the mechanistic data; however, we have no information on allergen exposure.

LMW phthalates were not positively associated with allergic symptoms or sensitization, except for MEP and allergic sensitization among Mexican Americans. All other race/ethnicity groups had inverse associations between sIgE and MEP. In addition, MEP was also inversely associated with hay fever and allergic sensitization in adults. In a previous NHANES sample (1999--2000), MEP levels among Mexican Americans were not different from non-Hispanic whites and were lower than for non-Hispanic blacks ([@r44]), suggesting exposure level did not explain the observed difference. Interestingly, in a study of Dominican (67%) and African-American (33%) children 5--9 years of age, [@r27] reported that children with higher urinary levels of MEP had higher fractional exhaled nitric oxide. There was limited evidence for differences between Dominican and African-American children for MEP exposure and allergic sensitization in children, but the sample sizes were small. In a Japanese cross-sectional study of 134 residents of 41 dwellings conducted in 2006--2007, DEP was inversely associated with respiratory and allergic symptoms in both children and adults, consistent with our results ([@r29]). It is possible that both age and race/ethnicity may influence allergic response to MEP, but currently the data are too limited to explore this extensively. MEP is the primary metabolite of DEP, a phthalate primarily used in fragrances ([@r2]). Some fragrances can be 25--50% DEP by volume ([@r1]). The inverse association with MEP and sensitization among adults could suggest fragrance avoidance by allergen-sensitized individuals. Among Mexican-American adults, we saw a positive association with MEP. Other investigators have noted that Mexican women who used multiple cosmetic and fragrance products had higher levels of MEP than those who did not, consistent with DEP exposure through the use of fragrances ([@r41]). The differential findings for Mexican Americans warrant further characterization of their exposures in the future.

Biological markers of phthalate metabolites are often used to assess exposure because of the complexity of evaluating all sources of exposure. Although the use of biological markers is common, these phthalate measures are limited with respect to the time period they represent. The biological half-lives of these metabolites are \< 1 day, and studies have shown that temporal variability in these measures limits their usefulness in estimating the associations with long-term exposure ([@r3]; [@r18]; [@r20]). Given the short biological half-lives of phthalates and the relatively nonvarying state of allergen-specific IgE in serum, our findings for allergic sensitization and HMW phthalates should be considered cautiously. These findings might reflect a preference for plastics among those with allergic sensitization because these surfaces are easier to clean and less likely to be reservoirs for dusts and other allergic triggers. In contrast, our findings for allergic symptoms are less challenged by the use of biological markers because symptoms were experienced within the past year, although daily variation in exposure may influence these findings as well.

Our limited findings for children were unexpected given the previous literature. HMW phthalates, particularly DEHP, were associated with current rhinitis, but none of the associations were statistically significant. In a Swedish study, dust levels of BBzP were associated with rhinitis and eczema in children 3--8 years of age, whereas dust levels of DEHP were associated with asthma; there was also some evidence of an association with rhinitis and DEHP in the highest quartile ([@r6]). Recently, [@r28] reported that prenatal exposure to MBzP was associated with maternally reported eczema by 5 years of age and that current exposures were associated with higher fractional exhaled nitric oxide ([@r27]). The HMW phthalate metabolites, MCOP and MCNP \[mono(carboxynonyl) phthalate\], were associated with current asthma in a cross-sectional study of 623 Norwegian 10-year-old children ([@r4]); these two metabolites were not associated with respiratory symptoms in children or adults in our sample. In our analysis, there was no evidence of an association of any phthalates with current itchy rash in either children or adults (data not shown). The lack of consistency with other studies may be related to the age of the children included in our analysis because no children \< 6 years of age had data on urinary phthalates. Another possible explanation is that the relevant exposures for children are not those that are currently occurring but rather those that occurred earlier, such as prenatally. In addition, our study included a large representative sample of children in the United States, whereas previous studies used smaller, more demographically similar groups. It may be that the diversity in our sample limited our ability to observe effects restricted to subsets of the population.

Phthalate metabolites, although chemically similar, are not highly correlated except for those derived from the same parent compound. To minimize confounding by correlated phthalates, we combined all metabolites from the same chemical (i.e., DEHP) into one summary variable. Given the multiple phthalates and ways to consider allergy and allergic sensitization, we conducted many statistical analyses. Rather than correcting our results for the number of comparisons or limiting our presentation to those chemicals for which we had *a priori* evidence, we have chosen to present our results uncorrected for multiple comparisons and present the full results in order to provide a more complete picture of the complexity of this research question.

Our previous work has shown poor concordance between self-reported respiratory symptoms and allergic sensitization ([@r21]). To evaluate if our results for respiratory symptoms were driven by allergic sensitization, we ran additional models for those who were both allergen sensitized and had the allergic symptom. These results suggested some interplay of allergic sensitization and symptoms in response to phthalates, but the evidence was inconclusive.

Conclusions
===========

This study is the largest to date to evaluate associations between phthalates and allergic sensitization and symptoms in both adults and children. Although not entirely consistent with previous studies, our study does provide additional evidence that phthalates, particularly HMW phthalates, may be associated with allergic symptoms in adults and possibly children. The findings were stronger in adults because HMW phthalates were generally positively associated with both allergic sensitization and symptoms in adults, but positively associated only with rhinitis in children. The inverse association estimated for MEP and allergic sensitization is consistent with avoidance of compounds containing DEP by people who are allergen sensitized. We conducted this cross-sectional analysis of urinary phthalate levels and allergic sensitization and symptoms in a large nationally representative racially diverse sample, although generalizability to younger children is limited by the lack of phthalate data for children \< 6 years of age. Future studies should not only better characterize the temporal association between exposure and outcome, but they should also include measures such as allergen exposure in order to better understand the potential mechanisms by which phthalates may contribute to allergic outcomes.
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